Format

Send to

Choose Destination
J Clin Apher. 2015 Feb;30(1):55-7. doi: 10.1002/jca.21349. Epub 2014 Sep 2.

Ulcerative colitis and granulocyte-monocyte-apheresis: safety and efficacy of maintenance therapy during pregnancy.

Author information

1
GI Unit, Department of Internal Medicine and Medical Specialties, Policlinico Umberto I, University of Rome "La Sapienza", Sapienza, University of Rome, Italy.

Abstract

Inflammatory bowel disease characteristically affects young adults in their reproductive ages. Thus the medication used for the treatment of active disease should not compromise fertility and, also, should not have teratogenic effect on baby. A lot of data are available about effects of steroids, antibiotics, and mesalazine but no data are available about safety and efficacy of granulocyte-monocyte-apheresis (GMA) during pregnancy. In this case report, the 37 year-old pregnant woman with chronically active and steroid dependent ulcerative colitis (UC), at risk of abortion, refused more aggressive pharmacological therapeutic options and gave the informed consent to GMA. To minimize symptoms and the risk of severe clinical relapse, a maintenance GMA treatment was performed throughout pregnancy. The course of pregnancy was uneventful with no side effects; the mother and the baby were all healthy and well at the delivery.

KEYWORDS:

granulocyte-monocyte-apheresis; pregnancy; ulcerative colitis

PMID:
25181523
DOI:
10.1002/jca.21349
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center